PMID- 32934892
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2164-2591 (Print)
IS  - 2164-2591 (Electronic)
IS  - 2164-2591 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Aug
TI  - Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine 
      Therapy.
PG  - 42
LID - 10.1167/tvst.9.9.42 [doi]
LID - 42
AB  - PURPOSE: To investigate the effect of systemic chloroquine/hydroxychloroquine 
      (CQ/HCQ) on outer retinal health using quantitative fundus autofluorescence (QAF) 
      imaging. METHODS: For this prospective, cross-sectional study, 44 CQ/HCQ patients 
      and 25 age-matched controls underwent multimodal retinal imaging including QAF 
      (488 nm) and spectral-domain optical coherence tomography (SD-OCT) in addition to 
      the recommended CQ/HCQ screening procedures. Custom written FIJI plugins enabled 
      detailed QAF analysis and correlation with retinal thickness and comparison to 
      the healthy controls. RESULTS: Out of 44 patients, 29 (mean age 43.5 +/- 12.2, 
      range 22-59 years) exposed to CQ/HCQ (mean cumulative dose 724.2 +/- 610.4 g, 
      median 608.0 g, range 18.6-2171.0 g) met eligibility criteria. Four of these 29 
      patients had bull's-eye maculopathy (BEM). Mean QAF values were significantly 
      higher in CQ/HCQ patients than in healthy controls. QAF increase started early 
      after treatment onset, remained high even years after treatment cessation, and 
      was not accompanied by pathologies in the other screening methods, including 
      retinal thicknesses (except in BEM patients). CONCLUSIONS: QAF might be a useful 
      tool in retinal imaging and in verifying systemic CQ/HCQ intake. The early onset 
      and preserved high levels of QAF parallel findings of CQ deposition in the retina 
      in animal models. Whether QAF can be used as a screening tool to detect early 
      CQ/HCQ related maculopathy is the subject of long-term ongoing studies. 
      TRANSLATION RELEVANCE: Experimental QAF imaging in systemic CQ/HCQ therapy 
      monitoring might be a useful tool to indicate the drug or its metabolites and to 
      detect metabolic retinal changes.
CI  - Copyright 2020 The Authors.
FAU - Reichel, Clara
AU  - Reichel C
AD  - University Hospital Wurzburg, Department of Ophthalmology, Wurzburg, Germany.
FAU - Berlin, Andreas
AU  - Berlin A
AD  - University Hospital Wurzburg, Department of Ophthalmology, Wurzburg, Germany.
FAU - Radun, Victoria
AU  - Radun V
AD  - University Hospital Wurzburg, Department of Ophthalmology, Wurzburg, Germany.
FAU - Tarau, Ioana-Sandra
AU  - Tarau IS
AD  - University Hospital Wurzburg, Department of Ophthalmology, Wurzburg, Germany.
FAU - Hillenkamp, Jost
AU  - Hillenkamp J
AD  - University Hospital Wurzburg, Department of Ophthalmology, Wurzburg, Germany.
FAU - Kleefeldt, Nikolai
AU  - Kleefeldt N
AD  - University Hospital Wurzburg, Department of Ophthalmology, Wurzburg, Germany.
FAU - Sloan, Kenneth R
AU  - Sloan KR
AD  - University of Alabama at Birmingham, Department of Ophthalmology, Birmingham, AL, 
      USA.
FAU - Ach, Thomas
AU  - Ach T
AD  - University Hospital Wurzburg, Department of Ophthalmology, Wurzburg, Germany.
AD  - University Hospital Bonn, Department of Ophthalmology, Bonn, Germany.
LA  - eng
GR  - R01 EY027948/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200828
PL  - United States
TA  - Transl Vis Sci Technol
JT  - Translational vision science & technology
JID - 101595919
RN  - 0 (Antirheumatic Agents)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 886U3H6UFF (Chloroquine)
MH  - Adult
MH  - Animals
MH  - *Antirheumatic Agents/adverse effects
MH  - Chloroquine/adverse effects
MH  - Cross-Sectional Studies
MH  - Fluorescein Angiography
MH  - Humans
MH  - *Hydroxychloroquine/adverse effects
MH  - Middle Aged
MH  - Prospective Studies
MH  - Young Adult
PMC - PMC7463177
OTO - NOTNLM
OT  - bulls eye maculopathy
OT  - chloroquine
OT  - hydroxychloroquine
OT  - quantitative fundus autofluorescence
COIS- Disclosure: C. Reichel, None; A. Berlin, None; V. Radun, None; I.-S. Tarau, None; 
      J. Hillenkamp, None; N. Kleefeldt, None; K.R. Sloan, MacRegen (I); T. Ach, 
      Novartis (F, R), Roche (C), MacRegen (I)
EDAT- 2020/09/17 06:00
MHDA- 2020/09/17 06:01
PMCR- 2020/08/28
CRDT- 2020/09/16 05:39
PHST- 2020/04/23 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/09/16 05:39 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/17 06:01 [medline]
PHST- 2020/08/28 00:00 [pmc-release]
AID - TVST-20-2534 [pii]
AID - 10.1167/tvst.9.9.42 [doi]
PST - epublish
SO  - Transl Vis Sci Technol. 2020 Aug 28;9(9):42. doi: 10.1167/tvst.9.9.42. 
      eCollection 2020 Aug.